Cardiology

You have access
SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists
CME article

Rahul Jaswaney, MD, Samantha Sokoloff, MD, Val Rakita, MD and Daniel J. Rubin, MD, MSc

Cleveland Clinic Journal of Medicine July 2024, 91 (7) 415-423; DOI: https://doi.org/10.3949/ccjm.91a.23093

This review summarizes recent data and guidelines regarding SGLT-2 inhibitors in heart failure and chronic kidney disease and provides practical guidance for their use.
You have access
In Reply: When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
Osamah Z. Badwan, MD, Venu Menon, MD and W. H. Wilson Tang, MD

Cleveland Clinic Journal of Medicine April 2024, 91 (4) 207-208; DOI: https://doi.org/10.3949/ccjm.91c.04002
You have access
When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
Aditya Sharma, MD, MHPE, FRCPC

Cleveland Clinic Journal of Medicine April 2024, 91 (4) 207; DOI: https://doi.org/10.3949/ccjm.91c.04001
You have access
2023 Update in ambulatory general internal medicine
Ashley Lim

Cleveland Clinic Journal of Medicine March 2024, 91 (3) 145-146; DOI: https://doi.org/10.3949/ccjm.91c.03001
You have access
In Reply: 2023 Update in ambulatory general internal medicine
Jason T. Alexander, MD, Simran K. Singh, MD, Sachin D. Shah, MD, Brianna Lambert, MD and Jeremy P. Smith, MD

Cleveland Clinic Journal of Medicine March 2024, 91 (3) 146; DOI: https://doi.org/10.3949/ccjm.91c.03002
You have access
When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
Cleveland Clinic Journal of Medicine February 2024, 91 (2) 118;

In the January 2024 issue, the article “When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?” by Badwan OZ et al [Cleve Clin J Med 2024; 91(1):47–51. doi:10.3949/ccjm.91a.23034] contained an error in Figure 1.
You have access
In Reply: Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
Pooja Prasad, MD and Megha Prasad, MD

Cleveland Clinic Journal of Medicine February 2024, 91 (2) 82-83; DOI: https://doi.org/10.3949/ccjm.91c.02002
You have access
Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
Taher Modarressi, MD

Cleveland Clinic Journal of Medicine February 2024, 91 (2) 82; DOI: https://doi.org/10.3949/ccjm.91c.02001
You have access
It’s a new year, looking back and looking forward
Brian F. Mandell, MD, PhD

Cleveland Clinic Journal of Medicine January 2024, 91 (1) 15-16; DOI: https://doi.org/10.3949/ccjm.91b.01024

Reflections on highlights from 2023 and impending changes in 2024, along with some acknowledgments and farewells.
You have access
Conjunctival petechiae in infective endocarditis
Akinori Sekizawa, MD, Ayaka Nagano, MD, Kenichi Hashimoto, MD, PhD and Yosuke Ono, MD, PhD

Cleveland Clinic Journal of Medicine January 2024, 91 (1) 20-21; DOI: https://doi.org/10.3949/ccjm.91a.23041

A 75-year-old-man presented with a 33-day history of intermittent nocturnal fevers of 39°C (102°F) and truncal rashes. The rashes appeared on the same day as the fever.

Main menu

User menu

Search

Cardiology

Pages

Navigate

Authors & Reviewers